Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Le Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3849-4854; OpenAlex author ID A5100450309. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 9

  1. Corrigendum to "Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis" [Cancer Lett. 481 (2020) 63-75]. Co-author DOI 10.1016/j.canlet.2025.218119↗
  2. Mechanism of Artemisia argyi in the Treatment of Pancreatic Ductal Adenocarcinoma Based on Network Pharmacology and Experimental Validation. Co-author DOI 10.2174/0118715206439346260326193041↗
  3. The liver casts a wide NET for metastatic pancreatic cancer. Co-author DOI 10.1038/s41591-024-03112-5↗
  4. Diabetic Ferroptosis and Pancreatic Cancer: Foe or Friend? Co-author DOI 10.1089/ars.2022.0101↗
  5. Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.655152↗
  6. Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis. Co-author DOI 10.1016/j.canlet.2020.02.039↗
  7. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway. Co-author DOI 10.1186/s13045-019-0837-z↗
  8. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1. First author DOI 10.1186/s13046-019-1278-9↗
  9. Silencing IGFBP-2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity. First author DOI 10.18632/oncotarget.18669↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rui Kong · 5 shared papers, 2017–2026 · strength 0.71
  2. Bei Sun · 4 shared papers, 2017–2022 · strength 0.43
  3. Qiushi Lin · 3 shared papers, 2019–2026 · strength 0.38
  4. Xuewei Bai · 3 shared papers, 2019–2026 · strength 0.38
  5. Lianxin Liu · 3 shared papers, 2019–2026 · strength 0.38
  6. Katsuya Nagaoka · 3 shared papers, 2019–2026 · strength 0.38
  7. Xiaoqun Dong · 3 shared papers, 2019–2026 · strength 0.38
  8. Jack R. Wands · 3 shared papers, 2019–2026 · strength 0.38
  9. Kosuke Ogawa · 3 shared papers, 2019–2026 · strength 0.38
  10. Howard P. Safran · 3 shared papers, 2019–2026 · strength 0.38
  11. Anirban Maitra · 1 shared paper, 2024 · strength 0.36
  12. Florencia M. McAllister · 1 shared paper, 2024 · strength 0.36
  13. Min Li · 2 shared papers, 2019–2026 · strength 0.30
  14. Jisheng Hu · 3 shared papers, 2017–2021 · strength 0.28
  15. Jian Guan · 1 shared paper, 2026 · strength 0.26
  16. Yan Luo · 1 shared paper, 2026 · strength 0.26
  17. Bei Sun · 1 shared paper, 2026 · strength 0.26
  18. Yongwei Wang · 3 shared papers, 2017–2020 · strength 0.23
  19. Yongwei Wang · 1 shared paper, 2026 · strength 0.22
  20. Chundong Cheng · 2 shared papers, 2019–2021 · strength 0.21
  21. Hongze Chen · 2 shared papers, 2019–2021 · strength 0.21
  22. Zhongjie Zhao · 2 shared papers, 2019–2021 · strength 0.21
  23. Bei Sun · 2 shared papers, 2019–2021 · strength 0.20
  24. Gang Wang · 1 shared paper, 2022 · strength 0.19
  25. Yilong Li · 2 shared papers, 2017–2019 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.